Braveheart Bio (NASDAQ:BRVE) Insider Acquires $19,998.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) insider Michele Anderson purchased 1,111 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $19,998.00. Following the completion of the transaction, the insider directly owned 332,161 shares in the company, valued at $5,978,898. This trade represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Braveheart Bio Stock Up 0.7%

Shares of NASDAQ BRVE traded up $0.20 during mid-day trading on Friday, reaching $30.00. 566,417 shares of the company’s stock were exchanged. Braveheart Bio, Inc. has a twelve month low of $28.47 and a twelve month high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.